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Genome-wide association studies (GWASs) have unraveled a large number of cancer risk alleles.
Understanding how these allelic variants predispose to disease is a major bottleneck confronting
translational application. In this issue, Li and colleagues combine GWASswith The Cancer Genome
Atlas (TCGA) to disambiguate the contributions of germline and somatic variants to tumorigenic
gene expression programs. They find that close to half of the known risk alleles for estrogen
receptor (ER)-positive breast cancer are expression quantitative trait loci (eQTLs) acting upon
major determinants of gene expression in tumors.Cancer is a complex trait affected by
the interaction of numerous somatically
acquired genetic and epigenetic lesions
influenced by underlying germline genetic
polymorphisms. Given that the most
effective disease intervention is preven-
tion, the detection of germline cancer
susceptibility loci is a growing focus of
several genome-wide association studies
(GWASs). A consistent theme elaborating
from these efforts is that common cancer
risk alleles are, for the most part, located
in intergenic and intronic chromosomal
regions with unknown functions (Hindorff
et al., 2011). Thus, the nature of the allele
does not usually reveal much about the
biology of the disease. Extensive public
efforts supporting large-scale, high-reso-
lution annotation of cancer genomes can
be leveraged to identify genes that are
directly modulated by cancer risk loci.
For example, The Cancer Genome Atlas
(TCGA) generates comprehensive profiles
of gene expression, epigenetic modifica-
tions, copy-number variation, and so-
matic mutations in tumors together with
matched constitutional DNA sequence
information. Application of these kinds of
orthogonal data sets to GWAS has lead
to the identification of 3 of the 19 colo-
rectal cancer risk alleles (Loo et al.,
2012), 3 of the 12 chronic lymphocytic
leukemia/small lymphocytic leukemia
risk alleles (Sille´ et al., 2012), and two
completely linked risk loci in lung cancersof nonsmokers (Li et al., 2010) as cis-
acting expression quantitative trait loci
(eQTLs), genomic loci that regulate
mRNA abundance.
In this issue of Cell, Li et al. (2013)
pursue the germline determinants of
gene expression in ER-positive and ER-
negative breast tumors. The identification
of such determinants may shed light on
the mechanistic contribution of cancer
risk loci on disease initiation and develop-
ment. However, the detection of function-
ally relevant germline alleles, using tumor-
derived gene expression data sets, is
confounded by log differences in the
sensitivity of gene regulatory programs
to the somatic variation present in tumor
tissue. The authors address this challenge
by treating germline and somatic variation
as independent variables in a multivariate
linear regression model built upon the
publicly available TCGA breast cancer
data sets. Using copy-number variation
and CpG island methylation to adjust
for the contribution of tumor-acquired
somatic abnormalities, the authors find
that cis-acting eQTLs account for 1.2%
of the total variance of gene expression
in ER-positive tumors, as compared to
somatic lesions, which account for 11%.
Of note, three of the detected eQTLs
directly mapped to 3 of 15 previously
discovered breast cancer risk loci: 2q35
(IGFBP5), 5q11 (C5orf35), and 16q21
(TOX3). Fortified by this correlation, theCell 152authors next devised a novel and effective
strategy to increase the sensitivity of
detection of cancer-susceptibility loci
that correspond to eQTLs. The basic
premise was that GWAS-identified risk
loci are enriched for cis-acting elements
for transcription factors—a notion sup-
ported to some extent by the analysis of
quantitative trait loci in model organisms
(Gerke et al., 2009). If true, then detection
of these relationships could be enhanced
by leveraging the amplification of small
changes in transcription factor abun-
dance on the expression variation of the
cohort of transcription factor client genes.
To test this, the authors first asked
whether any of the 12 unmapped breast
cancer risk loci were located near tran-
scription factors with DNA-binding motifs
enriched in the promoters of genes
with expression profiles that correlated
with the presence of the susceptibility
allele. They detected three new candidate
eQTLs associated with the risk loci 6q25/
ESR1, 9q31/KLF4, and 8q24/MYC. As ex-
pected for a bona fide eQTL target gene,
RNA-seq data showed significant allelic
imbalance for ESR1 and MYC in patients
that were heterozygous for the associated
risk locus. Importantly, chromosome
conformation capture (3C) revealed phys-
ical interactions between the risk loci and
their candidate target genes. The identifi-
cation of 6 out of 15 breast cancer list loci
as eQTLs, along with the annotation of the, January 31, 2013 ª2013 Elsevier Inc. 387
Figure 1. Bridging the Gap between Detection of Cancer Risk Loci and Development of
Disease Prevention Strategies
High-resolution annotation of molecular correlates in tumor samples can be dovetailed with GWAS to
elaborate causal relationships between risk loci and target genes. These target genes serve as both
functional and predictive biomarkers for personalized medicine. This, in turn, can lead to testable
mechanistic hypotheses and nomination of early detection and prevention strategies.gene expression program they modify, is
both technically and conceptually trans-
formative for understanding the patho-
genesis of breast cancer and holds
potential for the identification of additional
disease sites.
How can we improve our under-
standing of the 9 of 15 breast cancer risk
alleles unexplained by the methods em-
ployed in this study? The answer lies in
part with the challenge of annotating func-
tional interactions between germline
susceptibility loci and somatic variation.
eQTLs that primarily act in concert with
somatic mutations are likely to be difficult
or impossible to detect when modeled as
an independent variable. Asmentioned by
the authors, a more immediately address-
able challenge would be the consider-
ation of noncoding RNAs as eQTL target
genes. MicroRNAs, which were missed
in the present study due to the absence
of a comprehensive data table, are under
active investigation by many groups due
to their pro- and antitumorigenic activities388 Cell 152, January 31, 2013 ª2013 Elseviein a wide variety of tumor types. For
example, four different miRNAs, miR-7,
miR-128a, miR-210, and miR-516-3p,
were shown to be associated with dis-
ease aggressiveness in a study of 38
ER-positive lymph-node-negative breast
cancers (Foekens et al., 2008). Although
cis-eQTL analysis requires miRNA ex-
pression information that is not yet avail-
able for the TCGA breast tumor data set,
trans analysis may still be possible by
employing miRNA/mRNA target predic-
tions inmuch the sameway as the authors
employed transcription factor/mRNA
target predictions here. Both cis and trans
analyses that account for miRNAs as
potential eQTL targets are immediately
doable for the TCGA ovarian and glioblas-
toma multiform tumor data matrices.
How may these innovative approaches
and novel findings be translated to the
clinic? The discovery of cancer risk loci
that are eQTLs may provide a path
leading to early detection and prevention
strategies (Figure 1). A productive journeyr Inc.down this path is predicated on firmly
established causality. For example, the
relevance of estrogen receptor expres-
sion in luminal breast cancer is undeni-
able; it is a master regulator of tumori-
genic expression programs and is the
target of first-line hormonal therapy in
patients. However, it will be very impor-
tant to determine whether the ESR1
eQTL controls gene expression in normal
mammary epithelial cells in a similar
manner to that in breast cancers. This
could be greatly enabling for risk assess-
ment, early detection, and prevention
efforts. It remains to be assessed whether
women who carry the ESR1 eQTL risk
locus and ultimately develop breast
cancer exhibit this differential expression
in nonneoplastic mammary tissue as
compared to women that do not develop
the disease. The translation to the clinic
would then be to identify women with
the germline ESR1 eQTL, sample their
breasts (e.g., with fine-needle aspirates)
and screen for patients with the tumor-
phenotype-associated gene expression
pattern. These women could have both
more early detection follow-up but could
also be candidates for prevention therapy
targeting ESR1 with the available anties-
trogenic therapies currently used for
treating clinically evident breast cancers.
Discovering how the modulation of
eQTL target genes predisposes individ-
uals to cancer, and whether reprogram-
ming of the regulatory network mediated
by the target genes can reverse the
phenotype, also requires considerable
investment in preclinical experimental
models that would ideally be reflective of
the genetic diversity found in patient pop-
ulations. For example, excision of the
equivalent of a human colon cancer risk
locus upstream of MYC was sufficient to
inhibit APCmin-driven intestinal tumori-
genesis in the mouse (Sur et al.,
2012). Validation of ESR1, the gene en-
coding ER, as the functional target of the
6q25 breast cancer risk eQTL will illumi-
nate a solid path toward development
of genome-tailored early detection and
prevention tools.ACKNOWLEDGMENTS
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